Nanoscale, Год журнала: 2022, Номер 14(41), С. 15384 - 15392
Опубликована: Янв. 1, 2022
Nucleic acid therapy is attracting great attention in diverse clinical translations because of its therapeutic advantages.
Язык: Английский
Nanoscale, Год журнала: 2022, Номер 14(41), С. 15384 - 15392
Опубликована: Янв. 1, 2022
Nucleic acid therapy is attracting great attention in diverse clinical translations because of its therapeutic advantages.
Язык: Английский
Current Pharmaceutical Design, Год журнала: 2023, Номер 29(9), С. 640 - 651
Опубликована: Фев. 15, 2023
The self-assembly of peptides is very popular in biomedical fields. Peptide-based assemblies have been used as an ideal candidate for drug/gene delivery, tissue engineering, and antibacterial/anticancer agents. morphology structure peptide can be changed by altering the molecular conditions. Engineering present great potential medical In this review, function described. Also, advances peptide- based highlighted applications, such drug packaging antibacterial agents, siRNA-targeted delivery vaccines. Moreover, challenges future perspectives polypeptides are discussed.
Язык: Английский
Процитировано
6The AAPS Journal, Год журнала: 2023, Номер 25(6)
Опубликована: Окт. 2, 2023
Abstract Nanoparticles can encapsulate a range of therapeutics, from small molecule drugs to sensitive biologics, significantly improve their biodistribution and biostability. Whilst the regulatory approval several these nanoformulations has proven translatability, there remain hurdles translation future nanoformulations, leading high rate candidate failing during drug development process. One barrier is that difficulty in tightly controlling nanoscale particle synthesis leads particle-to-particle heterogeneity, which hinders manufacturing quality control, checks. To understand mitigate this heterogeneity requires advancements nanoformulation characterisation beyond traditional bulk methods more precise, single techniques. In review, we compare commercially available techniques, with particular focus on Raman spectroscopy, provide guide adoption into workflows, ultimately reduce barriers nanoformulations. Graphical
Язык: Английский
Процитировано
6Macromolecular Bioscience, Год журнала: 2023, Номер 24(4)
Опубликована: Дек. 27, 2023
RNA interference (RNAi) technology has been a promising treatment strategy for combating intractable diseases. However, the applications of RNAi in clinical are hampered by extracellular and intracellular barriers. To overcome these barriers, various siRNA delivery systems have developed past two decades. The first approved therapeutic, Patisiran (ONPATTRO) using lipids as carrier, amyloidosis is one most important milestones. This greatly encouraged researchers to work on creating new functional carriers. In this review, recent advances carriers consisting lipids, polymers, polymer-modified inorganic particles cancer therapy summarized. Representative examples presented show structural design order hurdles associated with therapies. Finally, existing challenges future perspective developing modality will be discussed proposed. It believed that addressed contributions review promote development applications.
Язык: Английский
Процитировано
6Macromolecular Bioscience, Год журнала: 2023, Номер 23(9)
Опубликована: Май 22, 2023
Abstract The efficacious delivery of therapeutic nucleic acids to cancer still remains an open issue. Through the years, several strategies are developed for encapsulation genetic molecules exploiting different materials, such as viral vectors, lipid nanoparticles (LNPs), and polymeric (NPs). Indeed, rapid approval by regulatory authorities wide use LNPs complexing mRNA coding spark protein COVID‐19 vaccination paved way initiation clinical trials therapy. Nevertheless, polymers represent a valuable alternative lipid‐based formulations, due low cost chemical flexibility that allows conjugation targeting ligands. This review will analyze status ongoing therapy, including immunotherapy approaches, materials. Among those nanosized carriers, sugar‐based backbones interesting category. A cyclodextrin‐based carrier (CALAA‐01) is first material enter trial complexed with siRNA chitosan one most characterized non‐viral vectors able complex material. Finally, recent advances in (oligo‐ polysaccharides) complexation advanced preclinical stage be discussed.
Язык: Английский
Процитировано
5Nanoscale, Год журнала: 2022, Номер 14(41), С. 15384 - 15392
Опубликована: Янв. 1, 2022
Nucleic acid therapy is attracting great attention in diverse clinical translations because of its therapeutic advantages.
Язык: Английский
Процитировано
8